Semaglutide Semaglutide is a long-acting GLP-1 RA approved both globally to treat type 2 diabetes and long-term weight management in obese or overweight patients aged 12 years and older - consistent with liraglutide
This may result in impaired tissue repair and regeneration and a decline in immune function
After muscle movement, it plays an essential role of providing the heart, muscles and body with required fatty acids
To address any uncertainty surrounding whether patients had collected and then taken their prescribed medication, which is a major limitation of prescription data, we conducted a more stringent sensitivity analysis in subgroups of patients who had at least two prescriptions for their GLP-1 RA in the baseline period, suggesting that they had used their first prescription
51 HF hospitalisations were significantly reduced in patients with a preserved, but not reduced, ejection fraction
Review findings The review emphasizes that the benefits of GLP-1 medicines are multi-organ and driven by complex mechanisms